The possibility of prevention of type 2 diabetes;Możliwości prewencji cukrzycy typu 2

Endokrynologia Polska

Volumn 59, Issue 1, 2008, Pages 6-12

  Strus, Adam ^a   Szepietowska, Barbara ^a   Zonenberg, Anna ^a   Nikołajuk, Agnieszka ^a   Górska, Maria ^a   Szelachowska, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetes mellitus type 2; Prevention; Treatment

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE TOLERANCE TEST; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OBESITY; RISK FACTORS; TRIGLYCERIDES;

EID: 42249084097     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Muggeo M. Accelerated complications in type 2 diabetes mellitus; the need for greater awareness and earlier detection. Diabet Med 1998; 15 (supl. 4): S60-S62.
2. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.(UKPDS 33). Lancet 1998; 352: 747-752.
3. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-years Malmo feasibility. Diabetologia 1991; 34: 891-898.
4. Pan XR, Li GW, Hu YH i wsp. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
5. Lindström J, Louheranta A, Mannelin M i wsp. The Finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236.
6. Melander A. Review of previous impaired glucose tolerance intervention studies. Diabet Med 1996; 13 (3 supl. 2): S20-S22.
7. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. Chiasson JL, Josse RG, Gomis R i wsp. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
9. Scheen AJ. Preventing, delaying or masking type 2 diabetes with metformin in the diabetes prevention program? Lancet 2003; 9: 2701.
10. Buchanan TA, Xiang AH, Peters RK i wsp. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-2803.
11. Burke JP, Williams K, Narayan KM i wsp. A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care 2003; 26: 1999-2004.
12. Szurkowska M, Szybiński Z, Nazim A i wsp. Chorobowoś ć z powodu cukrzycy typu 2 w populacji Krakowa. Pol Arch Med Wewn 2001; 106: 771-779.
13. Łopatynski J, Mardarowicz G, Nicer T i wsp. Badania nad wystȩpowaniem cukrzycy typu 2 w populacji powyżej 35 roku życia na wsi i w mieście w regionie lubelskim. Pol Arch Med Wewn 2001; 106: 781-786.
14. Drzewoski J, Saryusz-Wolska M, Czupryniak L. Wystȩpowanie cukrzycy typu 2 i wybranych zaburzeń metabolicznych w populacji miejskiej osób dorosłych powyżej 35 roku życia. Pol Arch Med Wewn 2001; 106: 787-791.
15. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8-13.
16. D'Agostino RB, Hamman RF, Karter AJ i wsp. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004; 27: 2234-2240.
17. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999; 42: 647-654.
18. Stratton IM, Adler AI, Neil HA i wsp. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
19. Creutzfeldt W. Effects of the alpha-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic implications. Diabetes Metab Res Rev 1999; 15: 289-296.
20. Kowalska I, Kinalska I, Telejko B. Glucose homeostasis in young adults without diagnosis of diabetes. Lancet 2002; 360: 1979.
21. Norhammar A, Tenerz A, Nilsson G i wsp. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144.
22. Bartnik M, Ryden L, Ferrari R i wsp. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-1890.